Although T-BsAb are designed to avoid the need for chemotherapy, recent studies of combination of chemotherapy and anti-CD19 T-BsAb (Blinatumomab) have shown improved survival rates in randomized clinical trials for standard-risk B cell acute lymphoblastic leukemia in children94. The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.